ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
02 Novembre 2023 - 9:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will participate in a fireside
chat at the upcoming Jefferies London Healthcare Conference. The
presentation is scheduled for November 15, 2023 at 9:30 am GMT /
4:30 am ET.
A webcast of the presentation will be accessible through the
“Investors and Media” section of the Company’s website,
www.immunogen.com. Following the live webcast, a replay will be
available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102139307/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Dic 2023 a Dic 2024
